Insmed Q3 2026 net loss narrows 73% year over year to $100.32 million
INSM•Insmed’s third-quarter 2026 net loss narrowed 73% year over year to $100.32 million, while revenue more than tripled to $524.43 million. The company raised full-year revenue guidance for BRINSUPRI and ARIKAYCE.
1. Quarterly results and guidance
Insmed’s third-quarter 2026 net loss narrowed 73% year over year to $100.32 million, and total revenue more than tripled to $524.43 million. BRINSUPRI revenue rose 29% from the second quarter to $400.1 million, driven by strong U.S. growth; Insmed raised its 2026 BRINSUPRI revenue guidance to $1.35 billion–$1.4 billion and ARIKAYCE guidance to $460 million–$470 million.
2. Japan launch
BRINSUPRI launched in Japan in October 2026 for non-cystic fibrosis bronchiectasis.
